A new study has proposed a mechanism for the pathogenesis of cerebral cavernous malformation (CCM) that links endothelial CCM3 deficiency to increased secretion of the vascular destabilizing protein angiopoietin-2 (ANGPT2).
blood-brain barrier, altered leptin signaling or attenuated inflammation and/or endoplasmic reticulum (ER) stress 4 . Lee and colleagues 2 add withaferin A to the list of novel leptin sensitizers by directly building upon their recent work on the ER stress agent celastrol 3 . They carried out microarrays on mouse embryonic fibroblasts undergoing celastrol treatment 2 and compared the ensuing ER stress signatures to a public collection of genome-wide transcriptional expression data derived from cells treated with one of more than 1,000 bio active small molecules. Subsequent connectivity mapping (CMAP) on the basis of similarities in expression patterns led to the identification calorie overconsumption and/or diet-induced obesity (DIO), leptin fails to activate hypothalamic anorexigenic circuitry. This failure is thought by many to result from either cellular or systemic resistance to leptin action in the brain. The subsequent failure to curb appetite leads to chronically higher food consumption and increasing body adiposity.
Recent reports of unimolecular polyagonists of gut-hormone receptors 1 or the plant constituent celastrol 3 offer some hope that overcoming leptin resistance could be a viable weight-loss option. The exact mechanism for this restoration of leptin sensitivity remains unclear, but it might entail improved leptin transport across the Over the past two decades, we have witnessed considerable efforts by numerous research organizations around the world to discover safe and efficacious weight-lowering drugs that have the potential to combat the continuously expanding obesity and type 2 diabetes pandemic. So far, however, the only therapeutic intervention with curative potential is bariatric surgery, such as gastric bypass. In additon, unimolecular combinatorial peptides aimed at mimicking endogenous signals that occur after gastric-bypass surgery seem to offer some promise, although they are only in the early stages of clinical testing 1 . By contrast, small-molecule drugs-often identified by costly high-throughput screens of extensive chemical libraries-have failed to show sufficient weight-lowering efficacy, and several drugs have been either rejected by regulatory authorities or withdrawn from the market because of adverse cardiovascular or psychiatric side effects 1 . In this issue of Nature Medicine, Lee and colleagues 2 make a potentially important contribution toward overcoming that challenge by identifying the small molecule withaferin A as a potential candidate for a therapy countering obesity and its metabolic side effects. They show in mice that withaferin A seems to harness endogenous weight-control machinery by restoring the sensitivity of the hypothalamus to leptin.
The satiety hormone leptin is secreted by adipocytes in direct proportion to fat mass, and activates anorexigenic circuitry in the hypothalamus of lean individuals, which thereby leads to diminished food intake and subsequent weight loss. Upon high fat intake, Obesity: will withaferin win the war?
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A new study shows that withaferin A, a steroidal lactone isolated from Withania somnifera, can exert profound metabolic benefits in mice, including body-weight loss, reduced hepatic steatosis and improved glucose control. Overall, both celastrol and withaferin A display near identical action profiles on ER stress and leptin sensitivity, as evidenced by distinct hypothalamic ER-stress gene signatures and improved efficacy of exogenous leptin in vivo toward reducing food intake and body weight in mice with DIO 2,3 . Accordingly, celastrol and withaferin A display high and leptindependent drug specificity when administered at low doses 2, 3 . However, previous reports that used higher doses of both compounds propose additional mechanisms of action [5] [6] [7] , and both compounds have indeed been considered as potential cytotoxicants and anticancer agents. In particular, anticarcinogenic activities of withaferin A and celastrol have been ascribed to their inhibition of heat-shock protein 90 (HSP90) and NF-κB signaling 6, 7 . Both pathways are also involved in the etiology of hypothalamic inflammation and metabolic dysfunction 8, 9 , and they might link celastrol and withaferin A action with improved bodyweight control and diabetes remission. Further studies are warranted to disentangle their mechanisms of action and the exact site(s) of action, which could entail-in addition to the hypothalamus-other brain areas and several peripheral tissues (Fig. 1) . In this context, the roles of adipose tissue and skeletal muscle deserve special attention, according to a recent study by Ma et al. 10 that suggests increased skeletal muscle nonshivering thermogenesis, subcutaneous adipose-tissue browning and brown-fat thermogenesis as major drivers for celastrol-induced weight loss, which are potentially mediated via heat-shock factor protein 1 (HSF1) and peroxisome proliferator-activated of withaferin A as a compound that had similar effects to celasterol.
The authors next assessed the weightlowering effect of withaferin A on mouse models with differential degrees of leptin resistance. In mice with DIO that display reversible leptin resistance 3,4 , 3 weeks of withaferin A treatment induced an impressive and apparently nontoxic weight-lowering effect, leading to a 23% reduction of body weight and 35% reduction of fat mass, as compared to vehicle-treated control mice with DIO, and near complete remission from hepatic steatosis. Withaferin A decreased body weight with substantially lower efficacy in lean mice with intact leptin sensitivity and in leptin-receptor-deficient (Lep db ) mice that have complete and irreversible leptin resistance. These data suggest that the effects of withaferin A on body weight and food intake are predominantly, but not exclusively, mediated via the restoration of central leptin sensitivity. By contrast, withaferin A displayed potent antidiabetic actions in both Lep db mice and mice with DIO, which suggests that the glucoregulatory roles of withaferin A are independent from leptin sensitivity and weight loss. The improvements in glucose tolerance and insulin sensitivity induced by withaferin A stand in stark contrast to the actions of celastrol, which showed no antidiabetic efficacy after low-dose treatment of mice with DIO or Lep db mice 3 . However, when administered at ten-fold higher doses, celastrol also decreased body weight, fat mass and insulin resistance in Lep db mice, potentially via the inhibition of inflammatory nuclear factor (NF)-κB signaling 5 .
receptor gamma co-activator-1α (PGC-1α, encoded by Ppargc1a).
Whether withaferin A will be effective in humans as a weight-loss and antidiabetic agent must be tested rigorously. Withaferin A is available orally and seems to be a naturally occurring leptin sensitizer capable of inducing impressive levels of weight loss and near complete remission from type 2 diabetes and hepatic steatosis in mice with DIO. A relatively broad spectrum of action, including such prominent pathways as NF-κB signaling or heat-shock proteins, might indicate considerable challenges for long-term safety and translation to humans. Yet a pharmacologically rich action profile could be what is required to achieve efficacy at a level that could alleviate the obesity and type 2 diabetes pandemic. Moreover, the CMAP-based drug-discovery approach by Lee et al. 2 might yield additional substances of therapeutic value.
The disruption or malformation of the vascular network can lead to various vascular diseases, such as CCM. CCM lesions are characterized by dilated thin-walled vessels that develop in the central nervous system. These malformed vessels disrupt the normal vascular architecture, and they are prone to rupture and leakage, which can cause cerebral hemorrhage, headache, stroke and seizure 1 . It is known that the familial type of CCM is caused by loss-of-function mutations in one of three genes: KRIT1 (also known as CCM1), CCM2 (also known as OSM) or PDCD10 (also known as CCM3) 2 . In normal cells, these three CCM gene products form an adaptor complex, which regulates several signaling pathways that are involved in endothelium stability control 3 . Mutations in any of these three genes are associated with endothelium destabilization.
There have been several independent models proposed for the pathogenesis of CCM in recent studies. The overall agreement is that CCM1 and CCM2 (hereafter CCM1/2) and CCM3 reside in separated signaling contexts, but their mutations lead eventually to quite npg
